Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.

The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda ...

As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley ...

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...

More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

Chinese clinical trials have become synonymous with speed and savings, but questions have surfaced about the price of those advantages. Reports surfaced over the summer of three deaths in Chinese ...